-
FACO | Zhong Jianhong / Su Jiayong: The More High-Risk Factors for Hepatocellular Carcinoma Recurrence, the Greater the Need for Adjuvant Therapy?
Q: Which presentations or discussions at this year’s FACO conference left the strongest impression on you? How might they influence your clinical practice? Dr. Su Jiayong: Thank you for the…
-
2025 FACO | Prof. Chao Chen: Building a Precision Model to Guide Immunotherapy for Liver Cancer, Looking to Broaden Validation Through Collaboration
Editor’s Note: China, Japan, South Korea and other East Asian countries share a high prevalence of hepatobiliary and pancreatic tumors, yet current treatment options still fall short of clinical needs.…
-
Professor Zhao Mingfeng: Focusing on CLL1 CAR-T to Explore New Pathways for Treating Acute Myeloid Leukemia ｜ 2025 International Cell & Immunotherapy Conference
To promote innovation in China’s cell and immunotherapy fields, deepen discussions on key scientific questions, share the latest clinical advancements, and foster global collaboration and clinical translation, the 2025 International Cell & Immunotherapy Conference (CTI 2025) was held in Hangzhou, Zhejiang, from November 13–16, 2025. The conference was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and was co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and Liangzhu Laboratory.
Connecting Medical Expertise through Media
